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Background
NNRTIs are very effective antiretrovirals, but new NNRTIs
with improved tolerability are needed.
Methods
A randomised Phase IIb study assessed the investigational
next-generation NNRTI, TMC278, 25, 75 and 150 mg QD
blinded up to 96 weeks and an open-label control, efa-
virenz (EFV) 600 mg QD in 368 treatment-naïve patients
(33% females). All patients received AZT/3TC (76%) or
TDF/FTC (24%).
Summary of results
No differences in efficacy were observed across TMC278
arms or vs. EFV at week 96. The potent antiviral efficacy of
TMC278 at week 48 was sustained to week 96. Mean
increase from baseline in CD4 cell count was higher at
week 96 vs. 48. (Table 1.)
At week 96 vs. week 48, there were few TMC278 dose-
related effects, and no change in types nor notable
increase in incidence of AEs. All rashes were grade 1 or 2,
except one case of grade 3 rash (TMC278 75 mg arm, dap-
sone-related). Rashes resolved with continued dosing
(median duration: all TMC278 17 vs. EFV 15 days). Inci-
dences of grade 3 or 4 nervous system AEs (no discontin-
uations; all TMC278: 0.7% vs. EFV: 1.1%) and psychiatric
AEs (1.8% vs. 1.1%) were low. Psychiatric AEs led to dis-
continuation in 0.4% vs. 2.2% of patients.
Conclusion
Over 96 weeks, TMC278 demonstrated a high, sustained
virological response rate and was generally well tolerated
with lower incidences of rash, nervous system and psychi-
atric AEs, and less lipid increases than EFV.
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TMC278 TMC278 TMC278 TMC278
Parameter Wk 25 mg qd (n = 93) 75 mg qd (n = 95) 150 mg qd (n = 91) All (n = 279) EFV 600 mg gd (n = 89)1
48 80(71–88) 80(72–88) 77(68–86) 79(74–84) 81(73–89)
VL <50 cps/mL (ITT-TLOVR algorithm), 
% 
(95% CI)
96 76(68–85) 72(62–81) 71(62–81) 73(68–78) 71(61–80)
Mean (SE) increase from baseline in CD4 
cell count, cells/mm3
48 122(12) 145(15) 143(15) 137(8) 127(11)
96 146(12) 172(16) 159(16) 159(9) 160(13)
AE incidence at Wk 96 (%)
Any AE 90 97 92 93 93
AEs leading to discontinuation 9 12 14 12 9
Any grade 3 or 4 AEs 30 25 26 27 21
Any serious AEs 13 14 10 12 15
Grade 3 or 4 lab abnormalities 33 22 24 27 24
AEs of interest* †
Any Rash 5 10 13 9‡ 21
Nervous system AEs 32 32 30 31‡ 48
Headache 17 23 19 20 16
Dizziness 13 10 10 11‡ 30
Somnolence 3 3 4 4§ 11
Psychiatric AEs 17 17 14 16 21
Insomnia 8 6 7 7 6
Depression 7 6 3 5 7
Abnormal dreams/nightmares 1 6 0 3 11
Mean (SD) changes from baseline 
in lipids (mg/dL)
Total cholesterol (TC) 10(28) 8(35) 9(29) 9(31)‡ 34(31
LDL-C 5(25) 5(30) 3(25) 5(27)‡ 18(28)
HDL-C 6(10) 7(11) 6(12) 6(11)‡ 11(12)
Ratio TC/HDL-C -0.4(1.3) -0.5(1.1) -0.3(1.0) -0.4(1.1) 0.1(0.9)
Triglycerides -8(75) -15(79) -7(90) -10(81)‡ 29(87)
1N = 88 for CD4; *Regardless of causality, occurring in ≥ 5% in any group; †well-described AEs for current NNRTIs; §p < 0.05, ‡p < 0.01 vs EFV; Fisher Exact test (AEs); non-
parametric Wilcoxon rank-sum test (lipids)Page 2 of 2
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